We have completed over 5,000 TMS treatments since 2019.
What Is TMS?
Treatment with Medication
To understand how successful TMS is, it’s important to understand just how successful other medications are.
- A large clinical study funded by the NIMH called the STAR*D study found that commonly prescribed medications, such as Selective Serotonin Reuptake Inhibitors (SSRIs), are only successful 27.5% of the time. However, if the SSRI doesn’t work (as is the case for many individuals with treatment-resistant depression), the success rate for medication decreases.
- By the fourth medication trial, the likelihood of reaching remission is a mere 7%.
- Given each medication trial can take 1-2 mo to assess response & tolerance, a chronically depressed patient may spend a minimum of 4-8 months bouncing from one medication to another, while the probability of reaching remission is dropping with time—with the likelihood of treatment failure approaching more than 90%.
- Not to mention, with each medication, there is the risk of poly-pharmacy, and the net risk to benefit ratio will become higher for risk, lower for benefit.
Pasadena Neuropsychiatry now has a Premium badge from BrainsWay. Badges indicate the number of BrainsWay treatments performed during the previous quarter or the number of treatment caps purchased during the trailing four quarters. Premier Providers are the highest tier.
Types of TMS Provided by Pasadena Neuropsychiatry
Available to the public since 2008, Transcranial Magnetic Stimulation is a non-invasive treatment for depression. The procedure sends out electromagnetic pulses from a figure-8-shaped handheld device, used to regulate the neural activity of brain structures found to be involved in depression.
While rTMS has been clinically shown to be a safe and effective treatment option, this original, standard form of TMS has certain limitations: The figure-8 coil’s relatively narrow scope means only a focal brain structure can be regulated at any given moment, causing targeting issues to arise during treatment. Standard rTMS also has trouble stimulating deeper structures directly, which can further affect its efficacy.
What Is DTMS Pasadena?
Deep Transcranial Magnetic Stimulation is an advancement on the standard, figure-8 rTMS treatment that manages to address the concerns raised with its predecessor. Deep TMS is also a non-invasive treatment that utilizes a magnetic field to safely and effectively regulate the neural activity of brain structures associated with depression, in addition to other forms of mental illness. Deep TMS does not require anesthesia or recovery, and can therefore be incorporated into an individual’s daily routine.
Brainsway FDA Clearances:
- Treatment-Resistant Depression
- Anxious Depression
- Smoking Cessation
- Theta-Burst for Treatment-Resistant Depression
An NIMH study discovered that SSRIs are effective for 27.5% of patients. If SSRIs are not effective, the chances of reaching remission by the fourth attempt with medication are 7 percent. Additionally, it can take four to 8 months to discover that there is a 90% chance of treatment failure.
BrainsWay dTMS™ has FDA clearance to treat both depression and OCD. The procedure is non-invasive and highly effective. The remission rate was 60% with dTMS and medication compared to 11% with medication alone. Additionally, patients whose treatments included dTMS and medicine had a 67% response rate compared to the 44% response rate of patients on medication who underwent rTMS.
At Pasadena Neuropsychiatry, we also utilize BrainsWay’s patented Deep TMS™ treatment as an innovative and effective option to treat depression and OCD.
At Pasadena Neuropsychiatry, we also utilizeBrainsWay’s patented Deep TMS™ treatment is an innovative and effective option to treat depression and OCD.
WHAT IS DTMS PASADENA FOR MDD?
BrainsWay D™ is leading a new era in the treatment and research of brain disorders. It offers relief for many patients suffering from life-altering conditions. It is a non-invasive and innovative treatment that is successfully transforming the lives of patients who suffer from Major Depressive Disorder (MDD). Thirty-three percent of MDD patients are resistant to any medication, and 52% fail to respond to first-line therapy. The U.S. Food and Drug Administration (FDA) cleared BrainsWay’s Deep TMS™ device to treat depression in patients who failed to respond to antidepressant medications. The treatment is well-tolerated and has been demonstrated to be effective in several clinical trials.*
BrainsWay D’s unique, patented treatment method stimulates deep and broad neuronal targets. The treatment involves deep magnetic stimulation of the bilateral prefrontal cortex, which has been shown to be responsible for depression. The stimulation has been shown to significantly improve depression symptoms in many people, leading to remission in about one-third of patients. Patients who have not seen improvement in their MDD symptoms using other treatment methods may finally find relief with BrainsWay.
DTMS in Pasadena for OCD
The FDA recently cleared BrainsWay D™ to treat Obsessive-Compulsive Disorder (OCD) for patients who have not responded well to traditional treatment methods. BrainsWay TMS™ can reach the anterior cingulate cortex and medial prefrontal cortex, which are associated with OCD. No other TMS system in the US has clearance for treating OCD. Deep TMS has been shown to alleviate symptoms in peer-reviewed clinical studies.
Theta Burst DTMS
The FDA has approved BrainsWay’s Theta Burst™ three-minute protocol using the dTMS system. These short sessions are shown to reduce depression, specifically, Major Depressive Disorder, significantly.
BrainsWay’s Theta Burst is also cleared by the FDA for Treatment-Resistant Depression (TRD) and Anxious Depression.
Theta Burst & PTSD
Along with these approved treatments, there is promising research suggesting that BrainsWay’s Theta Burst™ may be beneficial for PTSD and Addiction.
This off-label, out-of-pocket treatment modality may benefit many who end up in very expensive rehabs that are not actually evidence-based and have a high rate of relapse once the person is discharged.